Atrial functional mitral regurgitation
Atrial functional mitral regurgitation occurs secondary to left atrial disease, without left ventricular dilatation and intrinsic mitral valve disease. Atrial functional MR typically occurs in the setting of long-standing atrial fibrillation. It is associated with increased mortality risk and hospitalization for heart failure [1]. Reported prevalence of atrial functional MR in patients with AF vary between 3 to 15%. These patients have worse clinical outcome [2].
Dilatation of the mitral annulus, atriogenic tethering of mitral leaflets and insufficient mitral leaflet remodeling are thought to be important pathogenic mecha...
Source: Cardiophile MD - September 28, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Phosphodiesterase-9 inhibitors for the treatment of heart failure?
Phosphodiesterase-9 (PDE9) has the highest binding affinity among phosphodiesterases with cyclic guanosine monophosphate [1]. Cardioprotective effects of natriuretic peptides released in response to ventricular stretch in heart failure are mediated by the second messenger cyclic guanosine monophosphate (cGMP) [2]. Intracellular levels of cGMP and cAMP are governed by the activity of cyclic nucleotide phosphodiesterases. 11 phosphodiesterases with varying tissue selectivity and substrate affinity for cGMP and cAMP have been identified (PDE1 to PDE11) so far.
Increased mortality with high doses of PDE3 inhibitors milrinone,...
Source: Cardiophile MD - September 28, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Periodontal disease linked to heart failure – New study report
Periodontal disease linked to heart failure – New study report
Periodontal disease is known to be associated with coronary artery disease as well as poses a risk for bacteremia and subsequent risks [1]. A recent report looked at 6707 participants of the ARIC (Atherosclerosis Risk In Communities) study who had full-mouth periodontal examination at visit 4 between 1996-1998 and longitudinal follow up for incident heart failure. Data on incident heart failure was checked from visit 4 to 2018. In addition data on incident heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fract...
Source: Cardiophile MD - September 25, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Intravenous acetazolamide for acute decompensated heart failure – ADVOR Study
Intravenous acetazolamide for acute decompensated heart failure – ADVOR Study
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) study assessed whether intravenous acetazolamide can improve the efficacy of loop diuretics in acute decompensated heart failure with volume overload. Acetazolamide is a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption. It was a multicenter, double blind randomized, placebo controlled trial. Edema, pleural effusion and ascites were the important features of volume overload [1].
Ascites was confirmed by abdominal ultrasound and pleural eff...
Source: Cardiophile MD - September 24, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Finerenone, a non-steroidal MRA
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist. Finerenone is thought to have lower risk of hyperkalemia and renal issues compared to other MRAs. It has been shown to reduce albuminuria in patients with chronic kidney disease and type 2 diabetes mellitus. FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO-DKD) study evaluated the renal and cardiovascular outcomes in patients with CKD and type 2 diabetes mellitus. 5734 patients with CKD and type 2 diabetes were randomized to finerenone or placebo. All patients were on renin-angiotensin system blo...
Source: Cardiophile MD - September 24, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
DIAMOND trial: Patiromer for management of hyperkalemia in HFrEF
Patiromer is a nonabsorbed potassium binder used in the treatment of hyperkalemia. Earlier it was tested in patients with chronic kidney disease who were receiving inhibitors of the renin-angiotensin-aldosterone system (RAAS). It was found that patiromer treatment was associated with a decrease in serum potassium levels compared to placebo and a reduction in the recurrence of hyperkalemia [1].
DIAMOND trial was designed to evaluate patiromer for the management of hyperkalemia in patients receiving RAAS inhibitors for heart failure with reduced ejection fraction (HFrEF) [2]. 1195 patients with RAAS inhibitor related ...
Source: Cardiophile MD - September 24, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Weekly Overseas Health IT Links –17th September, 2022.
This study adds to the evidence showing that expanded access to these services could have a longer-term positive impact if continued.”Roughly 1 in 8 beneficiaries in the pandemic group received OUD-related telehealth services compared with 1 in 800 in the prepandemic group, the research revealed. Access to telehealth services was associated with better treatment retention and lower risk of medically treated overdose in the pandemic group compared to those not receiving telehealth services.-----https://healthimaging.com/topics/management/education-training/ai-deterring-students-pursuing-radiologyConcerns about the future ...
Source: Australian Health Information Technology - September 17, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Fight Aging! Newsletter, September 12th 2022
Discussion of Present Drug Development to Target Senescent Cells
Targeting Senescent Cells to Better Address Cancer and Consequences of Cancer Therapy
Calorie Restriction Suppresses Generation of Immune Cells via Changes to the Gut Microbiome
Arguing for an Expansion of the Hallmarks of Aging
https://www.fightaging.org/archives/2022/09/arguing-for-an-expansion-of-the-hallmarks-of-aging/
The hallmarks of aging form a catalog of largely better studied changes in cells and tissues considered relevant, and possibly more important, in the onset and development of age-related degeneration and disease. Thi...
Source: Fight Aging! - September 11, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Lesser Physical Function in Old Age Correlates with a Greater Cardiovascular Disease Risk
Better fitness in later life reduces mortality, and the study results here are just one of many examples that demonstrate this correlation, though specifically for cardiovascular disease in this case. While only correlations can be determined from most human data, animal studies make it quite clear that better fitness causes a reduced later life mortality. Maintaining better physical fitness is a good idea for many reasons, and it seems clear that health and longevity will benefit from doing so.
The Atherosclerosis Risk in Communities (ARIC) study, an ongoing community-based cohort enrolled 15,792 participants, ag...
Source: Fight Aging! - September 8, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Medicare Advantage Saves Lives, Limbs, Sight, And Major Amounts of Money – (Part 1)
BY GEORGE HALVERSON
Former Kaiser Permanente CEO George Halvorson has written on THCB on and off over the years, most notably with his proposal for Medicare Advantage for All post-COVID. He wrote a piece in Health Affairs last year arguing with the stance of Medicare Advantage of Don Berwick and Rick Gilfillan (Here’s their piece pt1, pt2). We also published his criticism (Part 1. Part 2. Part 3) of Medpac’s analysis of Medicare Advantage. Now Medpac is meeting again and George is wondering why they don’t seem to care about diabetic foot amputations. We are publishing part one today with part two com...
Source: The Health Care Blog - September 2, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: Health Policy Medicare Amputations Blindness George Halverson Medicare Advantage MedPAC Source Type: blogs
Cardiomyopathy in muscular dystrophies
Important muscular dystrophies due to mutations in structural cytoskeletal dystrophin gene are known as dystrophinopathies. They include Duchenne muscular dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy. Primary presentation of most dystrophinopathies is skeletal muscle weakness. Duchenne muscular dystrophy is caused by mutations leading to absence of functional dystrophin. Becker muscular dystrophy is due to mutations resulting in reduced amounts of shortened dystrophin protein.
Cardiac muscle being a striated muscle, is affected in many types of muscular dystrophies. Cardiomyopathy would contrib...
Source: Cardiophile MD - August 30, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
Biofourmis Raises Additional Funding from Intel Capital in Series D Extension and Names Top Healthcare Leaders to its Board
Additional funding brings Series D round to $320M total
Trevor Fetter, MBA, senior lecturer on the faculty of Harvard Business School and former longtime Tenet Healthcare chairman and CEO, named to Board
Sachin H. Jain, physician executive with government, pharmaceutical, payer and provider experience, joins Board
Biofourmis, a Boston-based global leader in virtual care and digital medicine, today announced that Intel Capital, the strategic investment arm of chipmaker Intel Corporation, has joined its Series D financing in an extension that brings the total funding raised in the round to $320M. The initial Series D funding...
Source: EMR and HIPAA - August 25, 2022 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Biofourmis Health IT Funding Health IT Fundings Health IT Investment Home-Based Care Intel Capital Kuldeep Singh Rajput Mark Rostick NYSE:CVS Sachin H. Jain Trevor Fetter Source Type: blogs
Long COVID cardiac studies: More questions than answers.
BY ANISH KOKA
The NIH recently announced $1.2 billion dollars in funding for research on Long COVID. This is in part because of a faction of scientists that have mined electronic health record databases to find evidence that the long term impacts of COVID on a variety of different organ systems is significant.
I have some concerns when it comes to the cardiac complications discussed related to Long COVID.
One of Dr. Al-Aly’s long COVID papers illustrates the issues with using large datasets to differentiate signal from noise. The authors used the US Department of Veterans Affairs national healthcare datab...
Source: The Health Care Blog - August 15, 2022 Category: Consumer Health News Authors: Ryan Bose-Roy Tags: COVID-19 Health Policy cardiac long covid studies NIH Source Type: blogs
Weekly Overseas Health IT Links – 13th August 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment-----https://ehrintelligence.com/news/va-appoints-functional-champion-for-ehr-modernization-programVA Appoints Functional Champion for EHR Modernization ProgramThe new functional champion appointment will assist the VA EHR Modernization program as it struggles with implementation delays and cost overruns, the VA stated.BySarai RodriguezAugust 05, 2022 - The Depart...
Source: Australian Health Information Technology - August 13, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Silicone Heart Models Heart Failure
Scientists at the Royal College of Surgeons in Ireland and partners at the National College of Art and Design in Dublin have developed a silicone heart model that is intended to model heart failure with preserved ejection fraction. The device, which represents a ‘mock circulatory loop’, includes a simulated version of the left atrium and left ventricle, and each chamber is independently controlled to model the entire cardiac cycle. The researchers use air pressure in a surrounding chamber to induce the device to pump, in much the same way that our diaphragm controls breathing by changing the air pressure in our thoraci...
Source: Medgadget - August 3, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Cardiac Surgery Cardiology RCSI Source Type: blogs
